16477-31-9

Basic information

• Product Name: 3-[(2,3-Dihydro-3-oxo-1,2-benzisothiazole 1,1-dioxide)-2-yl]-2,6-piperidinedione
• Synonyms: 3-[(2,3-Dihydro-3-oxo-1,2-benzisothiazole 1,1-dioxide)-2-yl]-2,6-piperidinedione
• CAS NO: 16477-31-9
• Molecular Formula: C₁₂H₁₀N₂O₅S
• Molecular Weight: 294.2832
• Mol File: 16477-31-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.618g/cm³
• Refractive Index: 1.66
• CAS DataBase Reference: 3-[(2,3-Dihydro-3-oxo-1,2-benzisothiazole 1,1-dioxide)-2-yl]-2,6-piperidinedione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(2,3-Dihydro-3-oxo-1,2-benzisothiazole 1,1-dioxide)-2-yl]-2,6-piperidinedione(16477-31-9)
• EPA Substance Registry System: 3-[(2,3-Dihydro-3-oxo-1,2-benzisothiazole 1,1-dioxide)-2-yl]-2,6-piperidinedione(16477-31-9)

Safety Data

• Hazardous Substances Data: 16477-31-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H10N2O5S/c15-10-6-5-8(11(16)13-10)14-12(17)7-3-1-2-4-9(7)20(14,18)19/h1-4,8H,5-6H2,(H,13,15,16)

Upstream product

• 62595-74-8 3-bromopiperidine-2,6-dione 
• 128-44-9 saccharin sodium salt 
• 39133-00-1 2-(2,3-dihydro-1,1-dioxido-3-oxo-1,2-benzisothiazol-2-yl)-glutaric acid-5-amide 

Relevant articles and documents

Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide

Compounds differing from thalidomide in either the phthalimide or the 2,6-dioxopiperidine moiety of the molecule were synthetized and tested for teratogenic potency in White New Zealand rabbits. Both the 2,6-dioxopiperidine and 2-oxopiperidine derivatives of phthalimide and phthalimidine were found to be highly teratogenic. A somewhat higher teratogenic potential appeared to be associated with the 2,6-dioxopiperidine derivatives. The most potent teratogen investigated was clearly 3-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-dioxopiperidine (EM 12). Compounds in which the phthalimide ring was replaced by 2,3-dihydro-1,1-dioxido-3-oxo-1,2-benzisothiazol, did not induce any embryopathic effect differing from control data. No consistent correlation between teratogenic activity and sedative properties of the compounds was detected. The results are discussed in respect to current views of the molecular mechanism leading to thalidomide embryopathy.